The Latin America, Middle East and Africa Mycoplasma Testing Market would witness market growth of 14.5% CAGR during the forecast period (2023-2030).
The market has seen a trend towards increased automation and adopting high-throughput technologies. Automated systems offer advantages such as higher efficiency, reduced turnaround times, and lower risk of contamination, making them appealing for laboratories dealing with many samples. There has been a growing interest in point-of-care testing for mycoplasma. Point-of-care devices offer rapid on-site testing capabilities, allowing quick decision-making and immediate corrective actions. This trend is particularly relevant in industries where real-time results are critical.
Advanced methods for this testing have led to incorporation due to ongoing developments in molecular biology. The heightened sensitivity and precision of digital polymerase chain reaction (PCR) and next-generation sequencing (NGS) in identifying mycoplasma contamination are being explored. The development and adoption of novel detection methods have been a notable trend. This includes exploring CRISPR-based technologies for mycoplasma detection, offering high specificity and sensitivity. These innovative approaches aim to improve accuracy and efficiency in identifying mycoplasma contamination.
The biopharmaceutical industry in Saudi Arabia may increasingly recognize the risks posed by mycoplasma contamination in cell cultures used for production. Academic and research institutions in Saudi Arabia may become more proactive in addressing mycoplasma contamination risks in their laboratories. The growing awareness can lead to the incorporation of this testing as a routine practice in research settings to maintain the integrity of experiments and data in Saudi Arabia. As awareness of mycoplasma contamination risks expands, healthcare professionals and researchers involved in cell-based therapies and regenerative medicine applications in Saudi Arabia may prioritize this testing to safeguard the safety and efficacy of patient-specific cell lines. Therefore, due to these aspects, the market will expand across the LAMEA region in upcoming years.
The Brazil market dominated the LAMEA Mycoplasma Testing Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $32.7 million by 2030. The Argentina market is showcasing a CAGR of 15.1% during (2023 - 2030). Additionally, The UAE market would register a CAGR of 14.2% during (2023 - 2030).
Based on Product & Service, the market is segmented into Kits & Reagents, Instruments and Services. Based on Technology, the market is segmented into PCR, ELISA, Microbial Culture Techniques, and Enzymatic Methods. Based on Application, the market is segmented into Cell Line Testing, Virus Testing, End of Production Cells Testing, and Others. Based on End User, the market is segmented into Pharmaceutical & Biotechnology Companies, Contract Research Organizations, Academic Research Institutes, Cell Banks, and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market has seen a trend towards increased automation and adopting high-throughput technologies. Automated systems offer advantages such as higher efficiency, reduced turnaround times, and lower risk of contamination, making them appealing for laboratories dealing with many samples. There has been a growing interest in point-of-care testing for mycoplasma. Point-of-care devices offer rapid on-site testing capabilities, allowing quick decision-making and immediate corrective actions. This trend is particularly relevant in industries where real-time results are critical.
Advanced methods for this testing have led to incorporation due to ongoing developments in molecular biology. The heightened sensitivity and precision of digital polymerase chain reaction (PCR) and next-generation sequencing (NGS) in identifying mycoplasma contamination are being explored. The development and adoption of novel detection methods have been a notable trend. This includes exploring CRISPR-based technologies for mycoplasma detection, offering high specificity and sensitivity. These innovative approaches aim to improve accuracy and efficiency in identifying mycoplasma contamination.
The biopharmaceutical industry in Saudi Arabia may increasingly recognize the risks posed by mycoplasma contamination in cell cultures used for production. Academic and research institutions in Saudi Arabia may become more proactive in addressing mycoplasma contamination risks in their laboratories. The growing awareness can lead to the incorporation of this testing as a routine practice in research settings to maintain the integrity of experiments and data in Saudi Arabia. As awareness of mycoplasma contamination risks expands, healthcare professionals and researchers involved in cell-based therapies and regenerative medicine applications in Saudi Arabia may prioritize this testing to safeguard the safety and efficacy of patient-specific cell lines. Therefore, due to these aspects, the market will expand across the LAMEA region in upcoming years.
The Brazil market dominated the LAMEA Mycoplasma Testing Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $32.7 million by 2030. The Argentina market is showcasing a CAGR of 15.1% during (2023 - 2030). Additionally, The UAE market would register a CAGR of 14.2% during (2023 - 2030).
Based on Product & Service, the market is segmented into Kits & Reagents, Instruments and Services. Based on Technology, the market is segmented into PCR, ELISA, Microbial Culture Techniques, and Enzymatic Methods. Based on Application, the market is segmented into Cell Line Testing, Virus Testing, End of Production Cells Testing, and Others. Based on End User, the market is segmented into Pharmaceutical & Biotechnology Companies, Contract Research Organizations, Academic Research Institutes, Cell Banks, and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
List of Key Companies Profiled
- Charles River Laboratories International, Inc.
- Thermo Fisher Scientific, Inc.
- Eurofins Scientific SE
- Lonza Group Ltd.
- Bio-Rad Laboratories, Inc.
- InvivoGen SAS
- Asahi Kasei Corporation
- F.Hoffmann-La Roche Ltd.
- Norgen Biotek Corp.
- PromoCell GmbH
Market Report Segmentation
By Product & Service- Kits & Reagents
- Instruments
- Services
- PCR
- ELISA
- Microbial Culture Techniques
- Enzymatic Methods
- Cell Line Testing
- Virus Testing
- End of Production Cells Testing
- Others
- Pharmaceutical & Biotechnology Companies
- Contract Research Organizations
- Academic Research Institutes
- Cell Banks
- Others
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. LAMEA Mycoplasma Testing Market by Product & Service
Chapter 5. LAMEA Mycoplasma Testing Market by Technology
Chapter 6. LAMEA Mycoplasma Testing Market by Application
Chapter 7. LAMEA Mycoplasma Testing Market by End User
Chapter 8. LAMEA Mycoplasma Testing Market by Country
Chapter 9. Company Profiles
Companies Mentioned
- Charles River Laboratories International, Inc.
- Thermo Fisher Scientific, Inc.
- Eurofins Scientific SE
- Lonza Group Ltd.
- Bio-Rad Laboratories, Inc.
- InvivoGen SAS
- Asahi Kasei Corporation
- F. Hoffmann-La Roche Ltd.
- Norgen Biotek Corp.
- PromoCell GmbH
Methodology
LOADING...
